Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1/A Registration statement (foreign)
- 4.19 Form of Common Warrant
- 4.20 Form of Pre-funded Warrant
- 4.21 Form of Placement Agent Warrant
- 5.1 Opinion of Conyers Dill & Pearman Limited, Bermuda Counsel to the Company, As to the Validity of the Common Shares of Altamira Therapeutics LTD.
- 5.2 Opinion of Lowenstein Sandler LLP, U.S. Counsel to the Company, As to the Validity of the Pre-funded Warrants, Common Warrants and Placement Agent Warrants
- 10.44 Form of Securities Purchase Agreement
- 23.1 Consent of Deloitte Ag
Associated filings
- 7 Jul 23 424B4 Prospectus supplement with pricing info
- 6 Jul 23 EFFECT Notice of effectiveness
-
3 Jul 23 F-1/A Registration statement (foreign) (amended)
- 16 Jun 23 F-1 Registration statement (foreign)
CYTO similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form F-1 of our report dated May 16, 2023, relating to the financial statements of Altamira Therapeutics Ltd., appearing in the Annual Report on Form 20-F of Altamira Therapeutics Ltd. for the year ended December 31, 2022. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
Deloitte AG
/s/ Roland Mueller | /s/ Adrian Kaeppeli | |
Zurich, Switzerland | ||
July 3, 2023 |